158 related articles for article (PubMed ID: 11584998)
1. Treatment of platinum-resistant ovarian cancer.
Trimble EL; Wright J; Christian MC
Expert Opin Pharmacother; 2001 Aug; 2(8):1299-306. PubMed ID: 11584998
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH
Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410
[TBL] [Abstract][Full Text] [Related]
3. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
4. [Epithelial ovarian cancer].
Hilpert F; Krause G; Venhoff L; Kühnle E; Schem C; Maass N
Ther Umsch; 2007 Jul; 64(7):375-80. PubMed ID: 17948754
[TBL] [Abstract][Full Text] [Related]
5. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.
Hetland TE; Kærn J; Skrede M; Sandstad B; Tropé C; Davidson B; Flørenes VA
Cancer Chemother Pharmacol; 2012 May; 69(5):1307-14. PubMed ID: 22302409
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer.
Siddiqui GK; Maclean AB; Elmasry K; Wong te Fong A; Morris RW; Rashid M; Begent RH; Boxer GM
Angiogenesis; 2011 May; 14(2):155-61. PubMed ID: 21221762
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive surgery in the management of ovarian cancer.
Schwartz PE
Oncology (Williston Park); 2008 Aug; 22(9):1025-33; discussion 1033-8, 1041, 1045. PubMed ID: 18777954
[TBL] [Abstract][Full Text] [Related]
8. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Oronsky B; Ray CM; Spira AI; Trepel JB; Carter CA; Cottrill HM
Med Oncol; 2017 Jun; 34(6):103. PubMed ID: 28444622
[TBL] [Abstract][Full Text] [Related]
9. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
Lin H; Changchien CC
Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
[TBL] [Abstract][Full Text] [Related]
10. Review of dose-intense platinum and/or paclitaxel containing chemotherapy in advanced and recurrent epithelial ovarian cancer.
Boere IA; van der Burg ME
Curr Pharm Des; 2012; 18(25):3741-53. PubMed ID: 22591417
[TBL] [Abstract][Full Text] [Related]
11. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
12. Second-Line Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian, Tubal and Peritoneal Cancer: A Propensity Score-Matching Study.
Lu CH; Chang YH; Lee WH; Chang Y; Peng CW; Chuang CM;
Chemotherapy; 2016; 61(5):240-8. PubMed ID: 26930357
[TBL] [Abstract][Full Text] [Related]
13. Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis.
Beesley VL; Green AC; Wyld DK; O'Rourke P; Wockner LF; deFazio A; Butow PN; Price MA; Horwood KR; Clavarino AM; Australian Ovarian Cancer Study Group ; Australian Ovarian Cancer Study-Quality Of Life Study Investigators ; Webb PM
Gynecol Oncol; 2014 Jan; 132(1):130-6. PubMed ID: 24125750
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.
Webber K; Friedlander M
Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():126-138. PubMed ID: 28027849
[TBL] [Abstract][Full Text] [Related]
15. Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Bonaventura A; OʼConnell RL; Mapagu C; Beale PJ; McNally OM; Mileshkin LR; Grant PT; Hadley AM; Goh JCH; Sjoquist KM; Martyn J; DeFazio A; Scurry J; Friedlander ML;
Int J Gynecol Cancer; 2017 Jun; 27(5):900-906. PubMed ID: 28498256
[TBL] [Abstract][Full Text] [Related]
16. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A
Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
[TBL] [Abstract][Full Text] [Related]
17. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies: tailored treatment for ovarian cancer: are we there yet?
Sessa C; Del Conte G
Nat Rev Clin Oncol; 2010 Feb; 7(2):80-2. PubMed ID: 20118979
[No Abstract] [Full Text] [Related]
19. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
20. Optimizing treatment in recurrent epithelial ovarian cancer.
Corrado G; Salutari V; Palluzzi E; Distefano MG; Scambia G; Ferrandina G
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1147-1158. PubMed ID: 29086618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
